Knopp is advancing dexpramipexole as an anti-inflammatory therapeutic based on extensive preclinical and clinical evidence of its activity in modulating white blood cells known as eosinophils.
The selective arrest of eosinophil maturation using orally available drugs presents the potential for novel treatments for inflammatory disease. Knopp is focused on identifying and modulating the molecular mechanisms underlying eosinophil differentiation.
Knopp is advancing novel agents to activate a key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as epilepsy and neuropathic pain.
The disruption of cellular bioenergetics has emerged as a common factor in pathways leading to cell death in ALS, Parkinson's, and other neurodegenerative disorders. Knopp's research is focused on small molecule modulators to improve mitochondrial efficiency.